Studying Biomarkers in Samples From Patients With Rhabdomyosarcoma

A Retrospective Study on the Diagnostic Value of Serum miR-206 in Rhabdomyosarcoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01433237

Enrollment

Registered

2011-09-13

Start date

2011-09-30

Completion date

2016-05-31

Last updated

2016-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcoma

Keywords

embryonal childhood rhabdomyosarcoma, adult rhabdomyosarcoma, alveolar childhood rhabdomyosarcoma, adult soft tissue sarcoma, childhood rhabdomyosarcoma

Brief summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies biomarkers in samples from patients with rhabdomyosarcoma.

Detailed description

OBJECTIVES: * Determine whether circulating muscle-specific microRNAs, especially serum miR-206, are potential biomarkers for rhabdomyosarcoma (RMS). OUTLINE: Archived serum samples are analyzed for miR-206 expression. PROJECTED ACCRUAL: A total of 15 samples from patients with alveolar rhabdomyosarcoma (RMS), 15 from patients with embryonal RMS, and 10 from patients without RMS will be accrued for this study.

Interventions

GENETICRNA analysis

GENETICgene expression analysis

OTHERlaboratory biomarker analysis

Study design

Observational model

CASE_CONTROL

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Serum specimens of rhabdomyosarcoma (RMS), embryonal RMS, and non-RMS available from the Soft Tissue Sarcoma committee of Children's Oncology Group PATIENT CHARACTERISTICS: * Not specified PRIOR CONCURRENT THERAPY: * Not specified

Design outcomes

Primary

Measure	Time frame
Serum miR-206 as a biomarker for RMS	—

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026